This therapy utilizes cord blood-derived NK cells transduced with a CAR targeting TROP2 and an IL-15 support gene, designed for IP delivery, to enhance tumor targeting in the peritoneal cavity. This evidence concerns the gene TACSTD2 and neoplasm.